ClinicalTrials.gg
WithdrawnNCT01731587FINGERPRINTUpdated Feb 28, 2017

Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer

A Phase 1 interventional study of Biological: MUC1 peptide specific immunotherapy and Cyclophosphamide (CPA) in Non-small Cell Lung Cancer (NSCLC) Stage III, sponsored by Merck KGaA, Darmstadt, Germany. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Basic science

Why this study was withdrawn
The objectives of this trial are no longer deemed appropriate for the clinical development of L-BLP25 therefore this trial is withdrawn

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 5 under way, none of them phase 3. Cyclophosphamide · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 19
0 · median 16
Started
2001
the only one that year
Phase 1
9 of 19
1 open now
Registered
8th of 19
by date
Lead sponsor
1 of 19
Merck KGaA, Darmstadt, Germany

Among the 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is the only one that started in 2001, is one of 9 in phase 1, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing cyclophosphamide in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Phase Ib study investigating whether liposome BLP25 mucin-1 (MUC1) peptide-specific immunotherapy (L-BLP25) administered as weekly subcutaneous doses over 8 weeks following a single dose of intravenous cyclophosphamide (CPA) induces a reproducible cytokine pattern measured in the serum of unresected Stage III non-small cell lung cancer (NSCLC) subjects after first-line chemo-radiation therapy.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC) Stage III

Keywords

  • Non-small cell lung cancer (NSCLC)
  • exploratory study
  • L-BLP25
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented unresectable Stage III NSCLC, as defined by American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) 7th edition (2009) criteria. All histological subtypes are acceptable, including bronchioalveolar carcinomas
  • Documented stable disease or objective response, according to (RECIST) Version 1.0, after primary chemo-radiotherapy (either sequential or concomitant) for unresected Stage III disease, within 4 weeks (28 days) prior to enrollment
  • Receipt of concomitant or sequential chemo-radiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of greater than equal to 50 Gray. Subjects must have completed the primary thoracic chemo-radiotherapy at least 4 weeks (28 days) and no later than 84 days prior to enrollment. Subjects who received prophylactic brain irradiation as part of primary chemo-radiotherapy are eligible
  • count greater than or equal to 140 * 10\^9 per liter, white blood cell (WBC) greater than or equal to 2.5 * 10\^9 per liter, and greater than or equal to 90 gram per liter
  • performance status (ECOG PS) of 0-1

Additional Inclusion Criteria apply

Exclusion criteria

Exclusion Criteria:

  • Pre-therapies:

    • Previous lung cancer specific therapy (including surgery) other than primary chemo-radiotherapy
    • Receipt of immunotherapy within 4 weeks (28 days) prior to enrollment. Note: Subjects who have received monoclonal antibodies for imaging are acceptable
    • Receipt of systemic drugs (including off-label use of approved products) within 4 weeks (28 days) prior to enrollment
  • Disease status:

    • disease
    • Malignant pleural effusion at initial diagnosis and/or at trial entry
    • Past or current history of neoplasm other than lung carcinoma, except for curatively treated nonmelanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
    • disease
    • A recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or congenital immunodeficiencies
    • Any preexisting medical condition requiring systemic chronic or therapy (steroids for the treatment of radiation pneumonitis are allowed)
    • Known and/or C
    • Active infection at enrollment, including but not limited to, flu-like infections, urinary tract infections, bronchopulmonary infections, etc
  • Physiological functions:

    • hepatic dysfunction (that is, [ALT] greater than 2.5 times normal upper limit []; or aspartate aminotransferase [AST] greater than 2.5 times ULN; or greater than or equal to 1.5 * ULN)
    • Clinically significant renal dysfunction (that is, serum creatinine greater than or equal to 1.5 * ULN)
    • Clinically significant cardiac disease, for example, (NYHA) Classes III-IV; uncontrolled angina, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction in the previous 6 months as confirmed by an (ECG)
    • Splenectomy
    • Infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response

Additional Exclusion Criteria apply

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    L-BLP25 plus Cyclophosphamide (CPA)

    Other: Biological: MUC1 peptide specific immunotherapy · Drug: Cyclophosphamide (CPA)

Interventions

  • OtherBiological: MUC1 peptide specific immunotherapy

    Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.

    Also known as: EMD531444, Stimuvax®

  • A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.

    Also known as: L01AA01, Endoxana

06

What researchers measure

Primary outcomes

  1. Immune response defined as change from baseline in serum cytokine levels after L-BLP25 administration at Week 1, 4 and 8

    Time frame: Pre-dose (Day -3) up to 24 hours after L-BLP25 administration at Week 1, 4 and 8

Secondary outcomes

  1. Evaluation of a cellular immune response following treatment with L-BLP25

    Time frame: Pre-dose (Day -3) and at 24 hours after L-BLP25 administration at Week 4 and 8

  2. Change from baseline in alternative immune or inflammatory serum soluble immune mediators such as interferon alpha (IFNα), transforming growth factor beta (TGFβ), or C-reactive protein (CRP) at 6, 12, and 24 hours after L-BLP25 administration.

    Time frame: Pre-dose (Day -3) up to 24 hours after L-BLP25 administration at Week 1, 4 and 8

  3. Number of subjects with adverse events (AEs)

    Time frame: Up to 6 weeks after the last dose of L-BLP25

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01731587
Responsible party
Sponsor
First posted
Nov 22, 2012
Start date
Jan 2001
Last update
Feb 28, 2017

Study contacts

Study Director
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion